ES2556534T3 - Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida - Google Patents
Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida Download PDFInfo
- Publication number
- ES2556534T3 ES2556534T3 ES13167178.6T ES13167178T ES2556534T3 ES 2556534 T3 ES2556534 T3 ES 2556534T3 ES 13167178 T ES13167178 T ES 13167178T ES 2556534 T3 ES2556534 T3 ES 2556534T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- disease
- reduced
- patient
- cognitive function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Un método para seleccionar un paciente para tratamiento de función cognitiva reducida relacionada con la enfermedad causada por reducción del metabolismo neuronal asociada a la enfermedad de Alzheimer (EA), método que comprende: a. seleccionar un paciente que tiene reducción de la función cognitiva relacionada con la enfermedad causada por reducción del metabolismo neuronal asociada a la enfermedad de Alzheimer (EA); b. determinar en el paciente la presencia de al menos uno de los genotipos específicos seleccionados entre el grupo que consiste en: i. homocigosis para citosina de rs2738447 de Receptor de Lipoproteína de Baja densidad (LDLR) en una porción relevante mostrada por la SEC ID Nº: 24, ii. homocigosis para guanina de LDLR rs7259278 en una porción relevante mostrada por la SEC ID Nº: 25, y iii. homocigosis para citosina de rs1799898 de LDLR en una porción relevante mostrada por la SEC ID Nº: 15; y c. seleccionar un paciente que tiene al menos uno de los genotipos específicos en (b) para tratamiento, en donde el tratamiento comprende la administración al paciente de al menos un triglicérido de cadena media (MCT) en una cantidad eficaz para el tratamiento o la prevención de la reducción de la función cognitiva relacionada con la enfermedad, causada por reducción del metabolismo neuronal asociada a la enfermedad de Alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95307407P | 2007-07-31 | 2007-07-31 | |
US953074P | 2007-07-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2556534T3 true ES2556534T3 (es) | 2016-01-18 |
ES2556534T9 ES2556534T9 (es) | 2016-07-06 |
Family
ID=40305284
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13167175.2T Active ES2556536T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
ES08796988.7T Active ES2608846T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
ES13167178.6T Active ES2556534T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
ES13167174.5T Active ES2556537T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
ES13167176.0T Active ES2556535T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
ES13167177.8T Active ES2608286T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13167175.2T Active ES2556536T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
ES08796988.7T Active ES2608846T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13167174.5T Active ES2556537T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
ES13167176.0T Active ES2556535T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
ES13167177.8T Active ES2608286T3 (es) | 2007-07-31 | 2008-07-31 | Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
Country Status (10)
Country | Link |
---|---|
US (2) | US9175345B2 (es) |
EP (6) | EP2650380B1 (es) |
JP (1) | JP5819065B2 (es) |
KR (1) | KR101335021B1 (es) |
CN (1) | CN101809443B (es) |
AU (1) | AU2008282130B2 (es) |
CA (3) | CA2694925C (es) |
ES (6) | ES2556536T3 (es) |
PT (6) | PT2650378E (es) |
WO (1) | WO2009018478A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
EP1929995A1 (en) | 2006-12-04 | 2008-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anaplerotic therapy of Huntington disease and other polyglutamine diseases |
PT2650378E (pt) | 2007-07-31 | 2016-01-14 | Accera Inc | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida |
CN105640931A (zh) | 2008-07-03 | 2016-06-08 | 艾克塞拉公司 | 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物 |
ES2640777T3 (es) * | 2009-12-30 | 2017-11-06 | Baylor Research Institute | Terapia anaplerótica para la enfermedad de Alzheimer |
EP2360280A1 (en) * | 2010-02-24 | 2011-08-24 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Genetic marker for the diagnosis of dementia with Lewy bodies |
CN104955450A (zh) | 2012-12-13 | 2015-09-30 | 达拉斯贝勒研究院 | 用于治疗葡萄糖转运体1缺乏症的三庚酸甘油酯 |
EP3068492B1 (en) | 2013-11-14 | 2020-01-08 | The University of Queensland | Neurodegenerative disorders and methods of treatment and diagnosis thereof |
CN104305192B (zh) * | 2014-10-23 | 2016-05-04 | 贡岳松 | 改善老年痴呆症患者记忆的功能性食品及其制备方法 |
WO2018212427A1 (ko) | 2017-05-15 | 2018-11-22 | 조선대학교산학협력단 | 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도 |
CN109480284A (zh) * | 2018-12-05 | 2019-03-19 | 上海欣海生物科技有限公司 | 一种生酮食品及其制备方法 |
KR20210135551A (ko) * | 2019-03-04 | 2021-11-15 | 세레신 인코포레이티드 | 개선된 생체이용률을 갖는 중쇄 트리글리세라이드 제제 및 이와 관련된 방법 |
CN112903885B (zh) * | 2019-12-03 | 2022-05-06 | 中国科学院大连化学物理研究所 | 一种筛查糖尿病的联合型代谢标志物的应用及其试剂盒 |
CN112226504B (zh) * | 2020-10-21 | 2021-06-08 | 北京市劳动保护科学研究所 | BuChE基因SNP位点的用途及新烟碱农药接触人群高TG血症易感性分析检测试剂盒 |
JP7414693B2 (ja) | 2020-11-09 | 2024-01-16 | 三協立山株式会社 | 建具 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2766146A (en) | 1954-07-26 | 1956-10-09 | Reynolds Tobacco Co R | Tobacco |
US2766145A (en) | 1954-07-26 | 1956-10-09 | Reynolds Tobacco Co R | Tobacco |
US3053677A (en) | 1959-11-12 | 1962-09-11 | Eastman Kodak Co | Petroleum wax for paper coatings |
US4112123A (en) | 1976-07-21 | 1978-09-05 | Beatrice Foods Co. | Nutritionally balanced single food composition and method of production |
US4346107A (en) | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
FR2490631A1 (fr) | 1980-09-24 | 1982-03-26 | Roussel Uclaf | Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique |
US4528197A (en) | 1983-01-26 | 1985-07-09 | Kabivitrum Ab | Controlled triglyceride nutrition for hypercatabolic mammals |
US4551523A (en) | 1983-04-14 | 1985-11-05 | Eastman Kodak Company | Preparation of saccharide acetoacetates |
US4847296A (en) | 1984-09-13 | 1989-07-11 | Babayan Vigen K | Triglyceride preparations for the prevention of catabolism |
US4687782A (en) | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
JPH0829055B2 (ja) | 1986-09-12 | 1996-03-27 | 大塚製薬株式会社 | 食品組成物 |
US5126373A (en) | 1987-11-19 | 1992-06-30 | Henri Brunengraber | Composition for parenteral and oral nutrition |
SE8803141L (sv) | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Naeringsmedel foer maenniskor och djur |
JP2654812B2 (ja) | 1988-09-24 | 1997-09-17 | コニカ株式会社 | 湾曲を防止したハロゲン化銀写真感光材料 |
US5118670A (en) | 1988-12-14 | 1992-06-02 | Massachusetts Institute Of Technology | Process and composition for increasing brain dopamine release |
US5650148A (en) | 1988-12-15 | 1997-07-22 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
DE3843238C1 (es) | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
IT1240775B (it) | 1990-02-23 | 1993-12-17 | Sigma Tau Ind Farmaceuti | Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma. |
JP2735927B2 (ja) | 1990-03-26 | 1998-04-02 | 鐘紡株式会社 | 密封容器入り中性飲料 |
CA2079890C (en) | 1990-04-26 | 1996-12-03 | James Carey Letton | Shortening compositions containing polyol fatty acid polyesters |
US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
US5175190A (en) | 1991-02-15 | 1992-12-29 | The University Of British Columbia | Medium chain fatty acids of C8-10 for the treatment of skin lesions |
US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
GB9113484D0 (en) | 1991-06-21 | 1991-08-07 | Unilever Plc | Cosmetic composition |
US5276059A (en) | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
US5308832A (en) | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
CZ181493A3 (en) | 1992-09-10 | 1994-03-16 | Lilly Co Eli | The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease |
DE625212T1 (de) | 1992-10-13 | 2000-11-02 | Univ Durham | Verfahren zum entdecken von krankheit von alzheimer. |
US5494794A (en) | 1992-10-20 | 1996-02-27 | Emory University | Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease |
JP3486778B2 (ja) | 1993-04-02 | 2004-01-13 | 三菱ウェルファーマ株式会社 | アルツハイマー病予防治療剤 |
JPH0725760A (ja) | 1993-07-09 | 1995-01-27 | Green Cross Corp:The | アルツハイマー病予防治療剤 |
WO1995009144A1 (en) | 1993-09-30 | 1995-04-06 | Eastman Chemical Company | Nutritive water soluble glycerol esters of hydroxy butyric acid |
US5420335A (en) | 1993-09-30 | 1995-05-30 | Birkhahn; Ronald H. | Parenteral nutrients based on watersoluble glycerol bisacetoacetates |
US5438042B1 (en) | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
JP3645580B2 (ja) | 1993-10-22 | 2005-05-11 | 株式会社フジモト・ブラザーズ | グルコースエステル誘導体を含有する脳代謝改善剤 |
US5691325A (en) | 1994-01-14 | 1997-11-25 | Sandyk; Reuven | Method for ameliorating age-related disease conditions |
US6251928B1 (en) | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
GB9408465D0 (en) | 1994-04-27 | 1994-06-22 | Univ Mcgill | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
US7049078B2 (en) | 1994-04-27 | 2006-05-23 | Judés Poirier | Apolipoprotein E polymorphism and treatment of alzheimer's disease |
US5607967A (en) | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
EP1719510A1 (en) | 1994-11-08 | 2006-11-08 | Avicenda Group, Inc. | Use of creatine or creatine analogs for the tratment of diseases of the nervous system |
US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
CA2214247C (en) | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
US6022683A (en) | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
JPH097785A (ja) | 1995-06-26 | 1997-01-10 | Mitsubishi Electric Corp | 放電灯点灯装置 |
AU6858696A (en) | 1995-08-24 | 1997-03-19 | Advanced Nutritionals Corporation | Carbohydrate and medium chain triglyceride gel as an energy supplement |
US5635199A (en) | 1995-10-27 | 1997-06-03 | Nestec Ltd. | Support of pediatric patients |
JP4598203B2 (ja) | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
US5936078A (en) | 1995-12-12 | 1999-08-10 | Kyowa Hakko Kogyo Co., Ltd. | DNA and protein for the diagnosis and treatment of Alzheimer's disease |
DE19609476A1 (de) | 1996-03-11 | 1997-09-18 | Basf Ag | Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen |
IT1284650B1 (it) | 1996-05-24 | 1998-05-21 | Sigma Tau Ind Farmaceuti | Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia |
KR980008239A (ko) | 1996-07-26 | 1998-04-30 | 김충환 | 사이클로스포린-함유 약학적 조성물 |
EP1006794B1 (en) | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
ES2530753T3 (es) | 1997-03-17 | 2015-03-05 | Btg Int Ltd | Composiciones terapéuticas que comprenden cuerpos cetónicos y precursores de los mismos |
US6316038B1 (en) | 1997-03-17 | 2001-11-13 | Btg International Limited | Therapeutic compositions |
JPH1198952A (ja) | 1997-09-29 | 1999-04-13 | Fuji Oil Co Ltd | 油脂含有食品及びその製造方法 |
US6352722B1 (en) | 1997-12-23 | 2002-03-05 | Quadrant Holdings Cambridge Limited | Derivatized carbohydrates, compositions comprised thereof and methods of use thereof |
US20040058873A1 (en) | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
JP2002510604A (ja) | 1998-04-02 | 2002-04-09 | アビセナ グループ, インク. | クレアチン化合物及び第二物質の組み合わせを含む組成 |
US6159942A (en) | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
AU4573799A (en) | 1998-06-19 | 2000-01-05 | Beth Israel Deaconess Medical Center | Dietary supplement for individuals under stress |
EP1098655B1 (en) | 1998-07-22 | 2004-11-24 | Metabolix, Inc. | Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
AU6039199A (en) | 1998-09-14 | 2000-04-03 | Pan Pacific Pharmaceuticals, Inc. | Useful properties of a bee venom protein and gene encoding same |
WO2000015216A1 (en) | 1998-09-15 | 2000-03-23 | Btg International Limited | Therapeutic compositions (ii) |
GB9908202D0 (en) | 1999-04-12 | 1999-06-02 | Unilever Plc | Cosmetic compositions |
US20070179197A1 (en) | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
ES2323940T3 (es) | 2000-05-01 | 2009-07-28 | Accera, Inc. | Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer. |
US6835750B1 (en) * | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
DE20012857U1 (de) | 2000-07-27 | 2000-11-09 | Sportmedizin Team Vertriebs Gm | Diätetisches Lebensmittel zum Fettabbau |
US6667397B2 (en) | 2000-08-25 | 2003-12-23 | Eastman Chemical Company | Methods of preparing disaccharide and trisaccharide C6-C12 fatty acid esters with high alpha content and materials therefrom |
GB2368011A (en) | 2000-10-17 | 2002-04-24 | Unilever Plc | Fatty acid esters of maltose and uses thereof |
US20020103139A1 (en) | 2000-12-01 | 2002-08-01 | M. Weisspapir | Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control |
KR100479741B1 (ko) | 2000-12-30 | 2005-03-30 | 주식회사 엘지생활건강 | 글루코오스 아실화 유도체 또는 수크로오스 아실화유도체를 함유하는 피부미백제 |
WO2002098398A1 (en) | 2001-06-07 | 2002-12-12 | Eisai Co., Ltd. | Methods for preventing and treating diseases and conditions associated with cellular stress |
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
US20030059824A1 (en) | 2001-09-21 | 2003-03-27 | Accera, Inc. | Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism |
AU2002364945A1 (en) | 2001-10-25 | 2003-07-09 | Neurogenetics, Inc. | Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases |
GB0128510D0 (en) | 2001-11-28 | 2002-01-23 | Novartis Ag | Organic compounds |
PT1529116E (pt) | 2002-08-07 | 2009-09-10 | Novartis Ag | Métodos para o tratamento da demência com base no genótipo da apo e |
US7320806B2 (en) | 2002-09-09 | 2008-01-22 | Vdf Futureceuticals, Inc. | Compositions and methods for treating NIDDM and other conditions and disorders associated with AMPK regulation |
US6884454B2 (en) | 2002-10-21 | 2005-04-26 | Julio Lionel Pimentel | Appetite suppressing diet bar |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
CA2517929A1 (en) | 2003-03-06 | 2004-09-16 | Accera Inc. | Novel-chemical entities and methods for their use in treatment of metabolic disorders |
ES2670413T3 (es) | 2003-06-03 | 2018-05-30 | The United States Government As Represented By The Department Of Health And Human Services | Suplementos nutricionales y composiciones terapéuticas que comprenden derivados de (R)-3-hidroxibutirato |
US20050013884A1 (en) | 2003-07-16 | 2005-01-20 | Rennels M. Scott | Compositions and methods for treating heart disease |
US7148192B2 (en) | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
AU2005249516B2 (en) | 2004-05-30 | 2010-11-18 | Sloan-Kettering Institute For Cancer Research | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
JP2006287138A (ja) | 2005-04-05 | 2006-10-19 | Mitsubishi Materials Corp | 受動部品形成用積層フィルム及びシート型受動部品並びにその製造方法 |
US20060252775A1 (en) | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
US8227408B2 (en) | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
AU2006326040B2 (en) | 2005-12-15 | 2012-02-09 | Société des Produits Nestlé S.A. | Compositions and methods for preserving brain function |
US20070173602A1 (en) | 2006-01-25 | 2007-07-26 | Brinkman Larry F | Encapsulated Michael addition catalyst |
EP2001293B9 (en) | 2006-04-03 | 2019-04-17 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
US7807718B2 (en) | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
JP2008104359A (ja) | 2006-10-23 | 2008-05-08 | Dainippon Ink & Chem Inc | 酵素固定用担体、固定化酵素および酵素固定用担体の製造方法 |
PT2650378E (pt) | 2007-07-31 | 2016-01-14 | Accera Inc | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida |
-
2008
- 2008-07-31 PT PT131671745T patent/PT2650378E/pt unknown
- 2008-07-31 EP EP13167176.0A patent/EP2650380B1/en active Active
- 2008-07-31 ES ES13167175.2T patent/ES2556536T3/es active Active
- 2008-07-31 ES ES08796988.7T patent/ES2608846T3/es active Active
- 2008-07-31 PT PT87969887T patent/PT2179284T/pt unknown
- 2008-07-31 EP EP13167175.2A patent/EP2650379B1/en active Active
- 2008-07-31 WO PCT/US2008/071817 patent/WO2009018478A2/en active Application Filing
- 2008-07-31 ES ES13167178.6T patent/ES2556534T3/es active Active
- 2008-07-31 ES ES13167174.5T patent/ES2556537T3/es active Active
- 2008-07-31 CA CA2694925A patent/CA2694925C/en active Active
- 2008-07-31 CN CN2008801095853A patent/CN101809443B/zh active Active
- 2008-07-31 CA CA2853992A patent/CA2853992C/en active Active
- 2008-07-31 ES ES13167176.0T patent/ES2556535T3/es active Active
- 2008-07-31 CA CA3078084A patent/CA3078084C/en active Active
- 2008-07-31 PT PT131671760T patent/PT2650380E/pt unknown
- 2008-07-31 EP EP08796988.7A patent/EP2179284B1/en active Active
- 2008-07-31 EP EP13167174.5A patent/EP2650378B1/en active Active
- 2008-07-31 JP JP2010520202A patent/JP5819065B2/ja active Active
- 2008-07-31 KR KR1020107004519A patent/KR101335021B1/ko active IP Right Grant
- 2008-07-31 PT PT131671778T patent/PT2650381T/pt unknown
- 2008-07-31 PT PT131671786T patent/PT2650382E/pt unknown
- 2008-07-31 US US12/671,610 patent/US9175345B2/en active Active
- 2008-07-31 EP EP13167177.8A patent/EP2650381B1/en active Active
- 2008-07-31 EP EP13167178.6A patent/EP2650382B9/en active Active
- 2008-07-31 AU AU2008282130A patent/AU2008282130B2/en active Active
- 2008-07-31 ES ES13167177.8T patent/ES2608286T3/es active Active
- 2008-07-31 PT PT131671752T patent/PT2650379E/pt unknown
-
2015
- 2015-10-09 US US14/879,744 patent/US10105338B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2556534T3 (es) | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida | |
Burgos et al. | Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA | |
Belzil et al. | Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients | |
DK1766077T3 (da) | Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse | |
Masi et al. | Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study | |
AR065910A1 (es) | Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b | |
GB2419882B (en) | Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer | |
Miyata et al. | Blood transcriptomic markers in patients with late-onset major depressive disorder | |
EA200800087A1 (ru) | Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа | |
ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
Opletalova et al. | Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum‐variant patients reveals 12 new disease‐causing POLH mutations | |
MX2011006091A (es) | Inhibidores de imidazopirazina syk. | |
ECSP088539A (es) | MÉTODO DE UTILIZACIÓN DE b-HIDROXI-b-METILBUTIRATO | |
ATE414177T1 (de) | Oligonukleotide zur genotypisierung des thymidylat-synthase gens | |
AR088294A1 (es) | Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero | |
JP2009504138A5 (es) | ||
DE112005001317A5 (de) | Polymorphismen im NOD2/Card15 Gen | |
WO2008088861A3 (en) | Gene polymorphisms predictive for dual tki therapy | |
Valdmanis et al. | Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden | |
ATE555814T1 (de) | Radioaktive mittel für die in vivo pet-bildgebung von ccr5 | |
Lozano et al. | Genomic studies in fragile X premutation carriers | |
WO2007095580A3 (en) | Treatment response in generalized social phobia | |
WO2007063405A3 (en) | Diagnosis and treatment of exocrine pancreatic dysfunction and diabetes using human cel gene | |
AR104348A1 (es) | Polimorfismos de un solo nucleótido seleccionados que son predictivos de respuestas al acetato de glatirámero | |
Milicic et al. | Utility of DNA Methylation as a Biomarker in Aging and Alzheimer’s Disease |